Literature DB >> 22492552

Heparin-modified dendrimer crosslinked collagen matrices for the delivery of heparin-binding epidermal growth factor.

M A Princz1, H Sheardown.   

Abstract

A tissue engineered corneal equivalent (TECEs) requires host integration to achieve adequate anchorage and long-term device stability. Corneal integration through epithelialization and stromal integration can be manipulated by growth factors. We investigated the potential of heparin-binding epidermal growth factor (HB-EGF) for mediating interactions with human corneal epithelial cells (HCEC) and compared its efficacy to epidermal growth factor (EGF) in vitro. Furthermore, we utilized heparinized dendrimer crosslinked collagen gels, intended for use as TECE, for delivery of HB-EGF in a sustained manner. HCEC were exposed to HB-EGF at varying concentrations between 0.1 and 1000 ng/mL. Cell proliferation increased with growth factor concentration up to a concentration of 50 ng/mL, suggesting growth factor receptor down-regulation at higher HB-EGF concentrations. Response to HB-EGF was comparable to EGF at low concentrations of 0.1 and 1 ng/mL but at a concentration of 10 ng/mL, HB-EGF induced significantly better proliferation than EGF. Proliferation was found to be dependent on the initial seeding density. Heparinized dendrimer crosslinked collagen (CHG) gels were capable of HB-EGF uptake, which was influenced by heparin concentration within the gel, growth factor concentration and exposure time to the growth factor. HB-EGF release followed first order kinetics, with ∼90% of the growth factor released after 2 weeks. Growth factor stability was verified with in vitro HCEC culture studies. Bioavailability was maintained in the gels through heparin interaction. Overall, HB-EGF induced proliferation of HCEC in vitro and can be released from heparinized collagen gels making it potentially suitable for promoting epithelialization of TECEs.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492552     DOI: 10.1002/jbm.a.34128

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  5 in total

1.  Forkhead Box q1 promotes invasion and metastasis in colorectal cancer by activating the epidermal growth factor receptor pathway.

Authors:  Jin-Jin Zhang; Chang-Xiong Cao; Li-Lan Wan; Wen Zhang; Zhong-Jiang Liu; Jin-Li Wang; Qiang Guo; Hui Tang
Journal:  World J Gastroenterol       Date:  2022-05-07       Impact factor: 5.374

Review 2.  Application of drug delivery systems for the controlled delivery of growth factors to treat nervous system injury.

Authors:  Fukai Ma; Fan Wang; Ronggang Li; Jianhong Zhu
Journal:  Organogenesis       Date:  2018-08-27       Impact factor: 2.500

3.  Controlled delivery of heparin-binding EGF-like growth factor yields fast and comprehensive wound healing.

Authors:  Noah Ray Johnson; Yadong Wang
Journal:  J Control Release       Date:  2012-11-12       Impact factor: 9.776

Review 4.  Strategies for local gene therapy of corneal allograft rejection.

Authors:  Pho Nguyen; Samuel C Yiu
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar

Review 5.  Glycosaminoglycan-based biomaterials for growth factor and cytokine delivery: Making the right choices.

Authors:  Daniel Hachim; Thomas E Whittaker; Hyemin Kim; Molly M Stevens
Journal:  J Control Release       Date:  2019-10-16       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.